Malaria Pathogenesis in young children and vaccine discovery

幼儿疟疾发病机制和疫苗发现

基本信息

项目摘要

In FY20, we reported human and animal studies to investigate malaria immunology and pathogenesis. Highlighted in this years summary are results from our publications. 1. Rodrigues DSA, Prestes EB, Silva LDS, Pinheiro AAS, Francischetti I, Saraiva E, Neto HAP, Bozza MT. 'CXCR4 and MIF are required for neutrophil extracellular trap release triggered by Plasmodium-infected erythrocytes in press with PLoS Pathogens. In press. Neutrophil extracellular trap (NET) evolved as an unique effector mechanism contributing to resistance against infection, that can also promote tissue damage in inflammatory conditions. Malaria infection can trigger NET release, but the mechanisms and consequences of NET formation in this context remain poorly characterized. Here we show that Plasmodium-infected erythrocytes cause the formation of NET by neutrophils from healthy donors in a mechanism dependent on the C-X-C chemokine receptor type 4 (CXCR4), activated by macrophage migration inhibitory Factor (MIF) release by infected erythrocytes. Patients suffering from cerebral malaria had increased amounts of circulating DNA, paralleled by increased NE activity in plasma. Importantly, mice infected P. berghei ANKA, a model of cerebral malaria, also had high amounts of circulating DNA, while treatment with DNAse increased parasitemia and accelerated mortality, indicating a role for NET in resistance against Plasmodium infection. 2. Raj DK, Mohapatra AD, Jnawali A, Zuromski J, Jha A, Cham-Kpu G, Sherman B, Rudlaff RM, Nixon CE, Hilton N, Oleinikov AV, Chesnokov O, Merritt J, Pond-Tor S, Burns L, Jolly G, Mamoun CB, Kabyemala E, Muehlenbachs A, Lambert L, Orr-Gonzalez S, Gndig NF, Fidock DA, Park S, Dvorin JD, Pardi N, Weissman D, Mui BL, Tam YK, Friedman JF, Fried M, Duffy PE, Kurtis JD. Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria. Nature. 2020 Jun;582(7810):104-108. doi: 10.1038/s41586-020-2220-1. Epub 2020 Apr 22. Malaria caused by Plasmodium falciparum remains the leading single-agent cause of mortality in children, yet the promise of an effective vaccine has not been fulfilled. Here, using our previously described differential screening method to analyse the proteome of blood-stage P. falciparum parasites, we identify P. falciparum glutamic-acid-rich protein (PfGARP) as a parasite antigen that is recognized by antibodies in the plasma of children who are relatively resistant-but not those who are susceptible-to malaria caused by P. falciparum. PfGARP is a parasite antigen of 80 kDa that is expressed on the exofacial surface of erythrocytes infected by early-to-late-trophozoite-stage parasites. We demonstrate that antibodies against PfGARP kill trophozoite-infected erythrocytes in culture by inducing programmed cell death in the parasites, and that vaccinating non-human primates with PfGARP partially protects against a challenge with P. falciparum. Furthermore, our longitudinal cohort studies showed that, compared to individuals who had naturally occurring anti-PfGARP antibodies, Tanzanian children without anti-PfGARP antibodies had a 2.5-fold-higher risk of severe malaria and Kenyan adolescents and adults without these antibodies had a twofold-higher parasite density. By killing trophozoite-infected erythrocytes, PfGARP could synergize with other vaccines that target parasite invasion of hepatocytes or the invasion of and egress from erythrocytes. 3. Raja AI, Brickley EB, Taaffe J, Ton T, Zhao Z, Bock KW, Orr-Gonzalez S, Thomas ML, Lambert LE, Moore IN, Duffy PE. A primate model of severe malarial anemia: a comparative pathogenesis study. Scientific Reports. 2019 Dec 12;9(1):18965. doi: 10.1038/s41598-019-55377-3. Severe malarial anaemia (SMA) is the most common life-threatening complication of Plasmodium falciparum infection in African children. SMA is characterised by haemolysis and inadequate erythropoiesis, and is associated with dysregulated inflammatory responses and reduced complement regulatory protein levels (including CD35). However, a deeper mechanistic understanding of the pathogenesis requires improved animal models. In this comparative study of two closely related macaque species, we interrogated potential causal factors for their differential and temporal relationships to onset of SMA. We found that rhesus macaques inoculated with blood-stage Plasmodium coatneyi developed SMA within 2 weeks, with no other severe outcomes, whereas infected cynomolgus macaques experienced only mild/ moderate anaemia. The abrupt drop in haematocrit in rhesus was accompanied by consumption of haptoglobin (haemolysis) and poor reticulocyte production. Rhesus developed a greater inflammatory response than cynomolgus macaques, and had lower baseline levels of CD35 on red blood cells (RBCs) leading to a significant reduction in the proportion of CD35+ RBCs during infection. Overall, severe anaemia in rhesus macaques infected with P. coatneyi has similar features to SMA in children. Our comparisons are consistent with an association of low baseline CD35 levels on RBCs and of early inflammatory responses with the pathogenesis of SMA. 4. Duffy PE. Immunity to Severe Malaria: PfEMP1 tags tell a tale. Cell Host & Microbe. 2019 Nov 13;26(5):571-573. doi: 10.1016/j.chom.2019.10.021. PfEMP1 is the major surface antigen of P. falciparum-infected erythrocytes, mediates endothelial adhesion, and displays extreme sequence diversity that underpins antigenic variation. In this issue of Cell Host & Microbe, Tessema et al. (2019) find that antibodies in sera from a pediatric cohort that bind a discrete PfEMP1 subset associate with protection from severe malaria and predict future risk. 5. Duffy PE. Structure solves the problem with malaria merozoite vaccines. Trends in Parasitology. 2019 Nov;35(11):855-857. doi: 10.1016/j.pt.2019.09.004. Malaria vaccines targeting merozoite invasion of erythrocytes have long held appeal but failed in clinical trials. Three structural studies of antibody-antigen complexes by Alanine et al., Urusova et al., and Rawlinson et al. define neutralizing and non-neutralizing epitopes in essential invasion proteins, leading to rational design of improved merozoite vaccines.
在2020财年,我们报告了人类和动物研究,以调查疟疾免疫学和发病机制。在今年的总结中突出显示的是我们出版物的结果。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Patrick Duffy其他文献

Patrick Duffy的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Patrick Duffy', 18)}}的其他基金

Malaria Surveillance and Research Studies in Liberia and Guinea-Conakry
利比里亚和几内亚科纳克里的疟疾监测和研究
  • 批准号:
    10272233
  • 财政年份:
  • 资助金额:
    $ 54.52万
  • 项目类别:
Malaria Transmission Blocking Vaccine Discovery
疟疾传播阻断疫苗的发现
  • 批准号:
    10272119
  • 财政年份:
  • 资助金额:
    $ 54.52万
  • 项目类别:
Malaria Vaccine: Pfs25-rEPA
疟疾疫苗:Pfs25-rEPA
  • 批准号:
    8745457
  • 财政年份:
  • 资助金额:
    $ 54.52万
  • 项目类别:
Pregnancy Malaria: Pathogenesis and Immunity
妊娠期疟疾:发病机制和免疫
  • 批准号:
    8745592
  • 财政年份:
  • 资助金额:
    $ 54.52万
  • 项目类别:
Gametocyte Carriage Rate and Transmission Blocking Vaccine Assay Development
配子体携带率和传播阻断疫苗检测的开发
  • 批准号:
    8745591
  • 财政年份:
  • 资助金额:
    $ 54.52万
  • 项目类别:
Malaria Vaccine: Pfs230
疟疾疫苗:Pfs230
  • 批准号:
    8745458
  • 财政年份:
  • 资助金额:
    $ 54.52万
  • 项目类别:
Assessment of whole organism vaccinations in Malian Adults
马里成人全身疫苗接种评估
  • 批准号:
    9161708
  • 财政年份:
  • 资助金额:
    $ 54.52万
  • 项目类别:
Malaria Transmission Blocking Vaccine Discovery
疟疾传播阻断疫苗的发现
  • 批准号:
    9161590
  • 财政年份:
  • 资助金额:
    $ 54.52万
  • 项目类别:
Malaria Vaccine: Pfs25-Pvs25
疟疾疫苗:Pfs25-Pvs25
  • 批准号:
    8336229
  • 财政年份:
  • 资助金额:
    $ 54.52万
  • 项目类别:
Malaria Vaccine: CSP-rEPA
疟疾疫苗:CSP-rEPA
  • 批准号:
    8336227
  • 财政年份:
  • 资助金额:
    $ 54.52万
  • 项目类别:

相似海外基金

Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 54.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The impact of changes in social determinants of health on adolescent and young adult mental health during the COVID-19 pandemic: A longitudinal study of the Asenze cohort in South Africa
COVID-19 大流行期间健康社会决定因素的变化对青少年和年轻人心理健康的影响:南非 Asenze 队列的纵向研究
  • 批准号:
    10755168
  • 财政年份:
    2023
  • 资助金额:
    $ 54.52万
  • 项目类别:
A Priority Setting Partnership to Establish a Patient, Caregiver, and Clinician-identified Research Agenda for Adolescent and Young Adult Cancer in Canada
建立优先合作伙伴关系,以建立患者、护理人员和临床医生确定的加拿大青少年和年轻人癌症研究议程
  • 批准号:
    480840
  • 财政年份:
    2023
  • 资助金额:
    $ 54.52万
  • 项目类别:
    Miscellaneous Programs
Incidence and Time on Onset of Cardiovascular Risk Factors and Cardiovascular Disease in Adult Survivors of Adolescent and Young Adult Cancer and Association with Exercise
青少年和青年癌症成年幸存者心血管危险因素和心血管疾病的发病率和时间以及与运动的关系
  • 批准号:
    10678157
  • 财政年份:
    2023
  • 资助金额:
    $ 54.52万
  • 项目类别:
Fertility experiences among ethnically diverse adolescent and young adult cancer survivors: A population-based study
不同种族青少年和年轻成年癌症幸存者的生育经历:一项基于人群的研究
  • 批准号:
    10744412
  • 财政年份:
    2023
  • 资助金额:
    $ 54.52万
  • 项目类别:
Treatment development for refractory leukemia using childhood/adolescent, and young adult leukemia biobank
利用儿童/青少年和青年白血病生物库开发难治性白血病的治疗方法
  • 批准号:
    23K07305
  • 财政年份:
    2023
  • 资助金额:
    $ 54.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular design of Two-Way Player CAR-T cells to overcome disease/antigen heterogeneity of childhood, adolescent, and young adult cancers
双向 CAR-T 细胞的分子设计,以克服儿童、青少年和年轻成人癌症的疾病/抗原异质性
  • 批准号:
    23H02874
  • 财政年份:
    2023
  • 资助金额:
    $ 54.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Effects of adolescent social isolation on adult decision making and corticostriatal circuitry
青少年社会隔离对成人决策和皮质纹状体回路的影响
  • 批准号:
    10756652
  • 财政年份:
    2023
  • 资助金额:
    $ 54.52万
  • 项目类别:
Adolescent trauma produces enduring disruptions in sleep architecture that lead to increased risk for adult mental illness
青少年创伤会对睡眠结构产生持久的破坏,从而导致成人精神疾病的风险增加
  • 批准号:
    10730872
  • 财政年份:
    2023
  • 资助金额:
    $ 54.52万
  • 项目类别:
Using Tailored mHealth Strategies to Promote Weight Management among Adolescent and Young Adult Cancer Survivors
使用量身定制的移动健康策略促进青少年和年轻癌症幸存者的体重管理
  • 批准号:
    10650648
  • 财政年份:
    2023
  • 资助金额:
    $ 54.52万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了